M. Hayat

5.5k citations

101 papers · 3.7k indexed · 1 hit paper · h-index 33

Impact in

Hematology top 1%
- Acute Myeloid Leukemia Research
- Hematopoietic Stem Cell Transplantation
Pathology and Forensic Medicine top 0.5%
- Lymphoma Diagnosis and Treatment

Papers in

Hematology 24
- Acute Myeloid Leukemia Research 14
- Hematopoietic Stem Cell Transplantation 13
Pathology and Forensic Medicine 36
- Lymphoma Diagnosis and Treatment 35

Co-authors: M Tubiana M. Henry‐Amar Patrice Carde L Schwarzenberg G Mathé Jeanne Amiel M. Schneider Jean Schlumberger
Journals: Journal of Clinical Oncology (7 papers)Blood (7 papers)Recent results in cancer research (5 papers)International Journal of Radiation Oncology*Biology*Physics (5 papers)Radiotherapy and Oncology (5 papers)
Partner nations: France Netherlands Belgium

In The Last Decade

M. Hayat

101 papers receiving 3.4k citations

Hit Papers

align trajectories log scale

ACTIVE IMMUNOTHERAPY FOR ACUTE LYMPHOBLASTIC LEUKÆMIA 1969 · 452 citations

Peers

Countries citing papers authored by M. Hayat

Since Specialization

Citations

This map shows the geographic impact of M. Hayat's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Hayat with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Hayat more than expected).

Fields of papers citing papers by M. Hayat

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Hayat. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Hayat. The network helps show where M. Hayat may publish in the future.

Co-authors

The 25 scholars most cited alongside M. Hayat, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with M. Hayat Line = papers co-authored together M. Hayat links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	A Comprehensive Review of Natural Fibers: Bio-Based Constituents for Advancing Sustainable Materials Technology JOURNAL OF RENEWABLE MATERIALS ·鈴木恵子, M. Hayat, С А Сечнев	2024	5
2	Prevention of Menstruation with Leuprorelin (GnRH Agonist) in Women Undergoing Myelosuppressive Chemotherapy or Radiochemotherapy for Hematological Malignancies: a Pilot Study Leukemia & lymphoma ·C. Lhommé, Abbas Naderi, J. H. Bourhis, Patricia Pautier, Nadine Dohollou, Molly Pinckston, Michael Ashman, C. G. Hsu, Valdano Manuel, M. Hayat	2001	12
3	Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group. Journal of Clinical Oncology ·Bob Löwenberg, Stefan Suciu, E Archimbaud, H. L. Haak, Pierre Stryckmans, Sosuke Kubo, A. W. Dekker, Zwi Berneman, A. Thyss, J. van der Lelie, Pieter Sonneveld, Giuseppe Visani, Georges Fillet, M. Hayat, A Hagemeijer, G. Solbu, R Zittoun	1998	218
4	Phase II trial of fludarabine monophosphate in patients with mantle-cell lymphomas. Journal of Clinical Oncology ·Didier Decaudin, J. Bosq, G. Tertian, G. Nedellec, Annelise Bennaceur‐Griscelli, A.M. Vénuat, C Bayle, Patrice Carde, Belguendouz Bendahmane, M. Hayat, J. N. Munck	1998	51
5	Should cytomegalovirus be tested for in both blood and bronchoalveolar lavage fluid of patients at a high risk of CMV pneumonia after bone marrow transplantation? British Journal of Haematology ·Carlos Becerril-Gutiérrez, Erwan Gautier, C Tolomio, Jean Bourhis, Anne Fajac, Jill JolineMyers, Alexandra Villing, P. Ficklscherer, C Tancrède, M. Hayat, Jean‐François Bernaudin, J L Pico	1997	10
6	Granulocyte-macrophage colony-stimulating factor associated with induction treatment of acute myelogenous leukemia: a randomized trial by the European Organization for Research and Treatment of Cancer Leukemia Cooperative Group. Journal of Clinical Oncology ·R Zittoun, Stefan Suciu, Franco Mandelli, T. de Witte, J. Thaler, Pierre Stryckmans, M. Hayat, M. Peetermans, M Cadiou, G. Solbu, Maria Concetta Petti, Roel Willemze	1996	96
7	Salvage treatment for primary resistant acute myelogenous leukemia consisting of intermediate-dose cytosine arabinoside and interspaced continuous infusions of idarubicin: A phase-II study (no. 06901) of the EORTC Leukemia Cooperative Group Annals of Hematology ·T de Witte, Stefan Suciu, Dominik Selleslag, Boris Labar, K. J. Roozendaal, R Zittoun, P. Alcántara, Ralph L.M. Kurstjens, M. Hayat, M Dardenne, G. Solbu, Petra Muus	1996	12
8	Prevention of oral mucositis in patients treated with high-dose chemotherapy and bone marrow transplantation: A randomised controlled trial comparing two protocols of dental care European Journal of Cancer Part B Oral Oncology ·Joaquin Hernández‐Bastida, E Benhamou, J.L. Pico, A. Laplanche, Patricia Janda, M. Hayat	1994	131
9	Clinical staging versus laparotomy and combined modality with MOPP versus ABVD in early-stage Hodgkin's disease: the H6 twin randomized trials from the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group. Journal of Clinical Oncology ·Patrice Carde, Anton Hagenbeek, M. Hayat, M. Monconduit, José Thomas, Juan Gabriel Arenas, Evert M. Noordijk, A Tanguy, J.H. Meerwaldt, R. Le Fur	1993	139
10	The EORTC trials for limited stage Hodgkin's disease European Journal of Cancer ·Jean‐Marc Cosset, M. Henry‐Amar, J.H. Meerwaldt, Patrice Carde, Evert M. Noordijk, José Thomas, J. M. V. Burgers, R. Somers, M. Hayat, M Tubiana	1992	47
11	Long-term survivors after salvage high dose chemotherapy with bone marrow rescue in refractory germ cell cancer European Journal of Cancer and Clinical Oncology ·Jean‐Pierre Droz, J. L. Pico, Mario Ghosn, Alain Gouyette, D Baume, G. Piot, M Ostronoff, Christine Théodore, F. Beaujean, M. Hayat	1991	36
12	Pericarditis and myocardial infarctions after Hodgkin's disease therapy International Journal of Radiation OncologyBiologyPhysics ·Jean‐Marc Cosset, M. Henry‐Amar, B. Pellae-Cosset, Patrice Carde, T. Girinski, M Tubiana, M. Hayat	1991	113
13	Causes of death after therapy for early stage Hodgkin's disease entered on EORTC protocols International Journal of Radiation OncologyBiologyPhysics ·M. Henry‐Amar, M. Hayat, J.H. Meerwaldt, Melissa Guadalupe Sagal Bustamante, Patrice Carde, R. Somers, E.M. Noordijk, M. Monconduit, José Thomas, Jean‐Marc Cosset, Emmanuel van der Schueren, R Regnier, Dominique Bron, Benjamin Magofsky, A Tanguy, Ben de Pauw, M Tubiana	1990	80
14	Phase II trial of idarubicin (4-demethoxydaunorubicin) in advanced breast cancer European Journal of Cancer and Clinical Oncology ·P Hurteloup, P. Armand, Martina Schneider, P Bastit, B Chevallier, Malahayati Rusli, R Keiling, Carlos Augusto Fernandes de Oliveira, M. Hayat, D. Thomas, M. van Glabbeke, Paul Rebattu, G Mathé	1989	12
15	Single dose versus hyperfractionated total body irradiation before allogeneic bone marrow transplantation: a non-randomized comparative study of 54 patients at the Institut Gustave-Roussy Radiotherapy and Oncology ·Jean‐Marc Cosset, D Baume, J.L. Pico, Brenda Shank, T. Girinski, E Benhamou, E. Briot, E.P. Malaise, M. Hayat, J Dutreix	1989	52
16	Clinical stages I and II Hodgkin's disease: a specifically tailored therapy according to prognostic factors. Journal of Clinical Oncology ·Patrice Carde, J M Burgers, M. Henry‐Amar, M. Hayat, D. Van Horn, Emmanuel van der Schueren, M. Monconduit, E.M. Noordijk, J Lustman-Maréchal, A Tanguy	1988	118
17	Phase II clinical trial with vindesine for remission induction in acute leukemia, blastic crisis of chronic myeloid leukemia, lymphosarcoma, and hodgkin's disease: absence of cross-resistance with vincristine. PubMed ·G Mathé, J. L. Misset, F. de Vassal, J. Gouveia, M. Hayat, D. Machover, D Belpomme, J. L. Pico, L Schwarzenberg, Patricia Ribaud, M Musset, C Jasmin, Luciana De Luca	1978	47
18	Hydroxyurea, Leucopheresis, and Splenectomy in Chronic Myeloid Leukaemia at the Problastic Phase BMJ ·L Schwarzenberg, G Mathé, P Pouillart, Roy S. Weiner, Guy Pesssach, Sayed Hossein Hosseinian, M. Schneider, F. de Vassal, M. Hayat, Jeanne Amiel, Jean Schlumberger, C Jasmin, Zeyu Wang	1973	21
19	Prognostic factors in 454 cases of Hodgkin's disease. PubMed ·M Tubiana, E Attié, R Flamant, R Gérard-Marchant, M. Hayat	1971	92
20	Pathogen-free isolation unit — Three years' experience BMJ ·M. Schneider, L Schwarzenberg, Jeanne Amiel, A Cattan, Jean Schlumberger, M. Hayat, F. de Vassal, Cheryl Jones, Xiaoyan Shentu, G Mathé	1969	13

About M. Hayat

M. Hayat is a scholar working on Hematology, Pathology and Forensic Medicine, Oncology, Genetics and Neurology, having authored 101 papers that have together received 3.7k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (35 papers), Lung Cancer Treatments and Mutations (16 papers), Cancer Treatment and Pharmacology (16 papers), Acute Myeloid Leukemia Research (14 papers), Acute Lymphoblastic Leukemia research (14 papers), Chronic Lymphocytic Leukemia Research (13 papers), Hematopoietic Stem Cell Transplantation (13 papers) and Neutropenia and Cancer Infections (13 papers). The work is most often cited by research in Hematology (989 citations), Pathology and Forensic Medicine (1.4k citations), Genetics (564 citations), Oncology (1.4k citations) and Otorhinolaryngology (140 citations). M. Hayat has collaborated with scholars based in France, Netherlands and Belgium. Frequent co-authors include M Tubiana, M. Henry‐Amar, Patrice Carde, L Schwarzenberg, G Mathé, Jeanne Amiel, M. Schneider, Jean Schlumberger, F. de Vassal and A Cattan. Their work appears in journals such as Journal of Clinical Oncology, Blood, Recent results in cancer research, International Journal of Radiation Oncology*Biology*Physics and Radiotherapy and Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact